NFE2L2 and ovarian carcinoma: Furthermore, we demonstrated that ATRA treatment suppressed the ALDH1A1-p62 axis, and thereby inhibited NRF2 activation, resulting in the attenuation of CSC-like properties only in ALDH1-high ovarian cancer cells.